[Successful use of vemurafenib in a patient with resistant hairy cell leukemia].

Abstract

The paper describes a case of a patient with refractory hairy cell leukemia. In spite of the absence of CD25 expression, the disease was classified as a classical form according to the WHO classification (2008), as also confirmed by the detection of BRAFV600E mutation. The disease was characterized by resistance to all lines of therapy (interferon-a, splenectomy, cladribin). Clinical and hematological remission was achieved within 2 months of administration of the BRAF kinase inhibitor vemurafenib.

• Authors: E S Urnova, L S Al'-Radi, L A Kuz'mina, A A Kariakina, A M Kovrigina, V N Dvirnyk, I A Iakutik, A B Sudarikov, E N Parovichnikova, V G Savchenko
• Journal: Terapevticheskii arkhiv (Ter Arkh) Vol. 85 Issue 7 Pg. 76-8 ( 2013) ISSN: 0040-3660 [Print] Russia (Federation)
• PMID: 24137951 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Indoles
• Sulfonamides
• Vemurafenib

Topics

• Antineoplastic Agents (administration & dosage, adverse effects, therapeutic use)
• Drug Resistance, Neoplasm
• Humans
• Indoles (administration & dosage, adverse effects, therapeutic use)
• Leukemia, Hairy Cell (complications, drug therapy, surgery)
• Male
• Middle Aged
• Splenectomy
• Splenomegaly (complications, surgery)
• Sulfonamides (administration & dosage, adverse effects, therapeutic use)
• Treatment Outcome
• Vemurafenib